Vasculitis Drug Pipeline Analysis Report 2025
Description
According to a study published in BMJ Journals, in Europe and the USA, the yearly incidence of primary systemic vasculitis is thought to be between 20 and 40 cases per million individuals. In Europe and the USA, the estimated yearly incidence of primary systemic vasculitis is between 20 and 40 cases per million individuals.
Report Coverage
The Vasculitis Drug Pipeline Report by Expert Market Research gives comprehensive insights into vasculitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vasculitis. The report includes the analysis of over 10 pipeline drugs and 5+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vasculitis.
The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing vasculitis pipeline development activities are covered in this report.
Vasculitis Drug Pipeline Outlook
Vasculitis is a collection of uncommon illnesses that causes inflammation of the blood vessels, which damages the walls of the vessels. This inflammation may weaken, narrow, or scar the vessels, which could impair blood flow and perhaps cause harm to the organs or tissues. Vasculitis can be brought on by infections, autoimmune diseases, or specific drugs, however, its precise origin is frequently unknown. Genetic factors may be involved in some cases. Any age or gender can be affected by vasculitis, while some sub-types may only affect particular groups of people.
The main goals of vasculitis treatment are to reduce inflammation and stop new blood vessel damage. Depending on the organs, type, and degree of involvement, several approaches are used. Prednisone and other corticosteroids are frequently used to treat inflammation, frequently in conjunction with immunosuppressive medications like methotrexate or cyclophosphamide to suppress the immune system. Biologic medications such as rituximab may be recommended in severe situations. Regular monitoring for drug adverse effects and illness progression is part of management. To improve quality of life and supportive care, which also includes physical therapy and pain management is essential. Surgery could be required in some circumstances to fix broken blood vessels. Lifestyle changes that promote general health and rehabilitation include quitting smoking, maintaining a balanced diet, and engaging in regular exercise.
Vasculitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vasculitis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 30+ drug analyses based on phase.
EMR’s vasculitis therapeutic assessment report covers 30+ drug analyses based on molecule type:
EMR’s pipeline assessment report covers 30+ drug analyses based on the route of administration.
The vasculitis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for vasculitis with 5 pipeline drugs in phase III.
Vasculitis – Pipeline Assessment Segmentation, By Molecule Type
The drug molecules categories covered under vasculitis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptide, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Stud ies that target monoclonal antibodies have been highly effective in the management of vasculitis. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for vasculitis.
Vasculitis Clinical Trials Assessment – Competitive Dynamics
The EMR vasculitis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vasculitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vasculitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vasculitis drug candidates.
Drug: Benralizumab
The trial evaluates the efficacy and safety of benralizumab in patients with vasculitis. The trial is sponsored by AstraZeneca and is currently under phase III.
Drug: Upadacitinib
The study evaluates the efficacy of upadacitinib for the treatment of vasculitis. The trial is sponsored by Abbvie Inc. and is currently under phase III.
Drug: Secukinumab
To assess the efficacy and safety of secukinumab in patients with vasculitis. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase III.
Reasons to Buy This Report
The Vasculitis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for vasculitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vasculitis pipeline insights.
Key Questions Answered in the Vasculitis – Pipeline Insight Report
Global Psoriatic Arthritis Treatment Market
Global Plaque Psoriasis Treatment Market
Global Psoriasis Treatment Market
Report Coverage
The Vasculitis Drug Pipeline Report by Expert Market Research gives comprehensive insights into vasculitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vasculitis. The report includes the analysis of over 10 pipeline drugs and 5+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vasculitis.
The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing vasculitis pipeline development activities are covered in this report.
Vasculitis Drug Pipeline Outlook
Vasculitis is a collection of uncommon illnesses that causes inflammation of the blood vessels, which damages the walls of the vessels. This inflammation may weaken, narrow, or scar the vessels, which could impair blood flow and perhaps cause harm to the organs or tissues. Vasculitis can be brought on by infections, autoimmune diseases, or specific drugs, however, its precise origin is frequently unknown. Genetic factors may be involved in some cases. Any age or gender can be affected by vasculitis, while some sub-types may only affect particular groups of people.
The main goals of vasculitis treatment are to reduce inflammation and stop new blood vessel damage. Depending on the organs, type, and degree of involvement, several approaches are used. Prednisone and other corticosteroids are frequently used to treat inflammation, frequently in conjunction with immunosuppressive medications like methotrexate or cyclophosphamide to suppress the immune system. Biologic medications such as rituximab may be recommended in severe situations. Regular monitoring for drug adverse effects and illness progression is part of management. To improve quality of life and supportive care, which also includes physical therapy and pain management is essential. Surgery could be required in some circumstances to fix broken blood vessels. Lifestyle changes that promote general health and rehabilitation include quitting smoking, maintaining a balanced diet, and engaging in regular exercise.
Vasculitis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vasculitis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 30+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s vasculitis therapeutic assessment report covers 30+ drug analyses based on molecule type:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptides
- Polymer
- Gene Therapy
EMR’s pipeline assessment report covers 30+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The vasculitis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for vasculitis with 5 pipeline drugs in phase III.
Vasculitis – Pipeline Assessment Segmentation, By Molecule Type
The drug molecules categories covered under vasculitis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptide, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Stud ies that target monoclonal antibodies have been highly effective in the management of vasculitis. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for vasculitis.
Vasculitis Clinical Trials Assessment – Competitive Dynamics
The EMR vasculitis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vasculitis clinical trials:
- AstraZeneca plc
- Smith & Nephew, Inc.
- Abbvie Inc.
- Novartis Pharmaceuticals
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vasculitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vasculitis drug candidates.
Drug: Benralizumab
The trial evaluates the efficacy and safety of benralizumab in patients with vasculitis. The trial is sponsored by AstraZeneca and is currently under phase III.
Drug: Upadacitinib
The study evaluates the efficacy of upadacitinib for the treatment of vasculitis. The trial is sponsored by Abbvie Inc. and is currently under phase III.
Drug: Secukinumab
To assess the efficacy and safety of secukinumab in patients with vasculitis. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase III.
Reasons to Buy This Report
The Vasculitis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for vasculitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vasculitis pipeline insights.
Key Questions Answered in the Vasculitis – Pipeline Insight Report
- Which companies/institutions are leading the vasculitis drug development?
- What is the efficacy and safety profile of vasculitis pipeline drugs?
- Which company is leading the vasculitis pipeline development activities?
- What is the current vasculitis commercial assessment?
- What are the opportunities and challenges present in the vasculitis drug pipeline landscape?
- What is the efficacy and safety profile of vasculitis pipeline drugs?
- Which company is conducting major trials for vasculitis drugs?
- Which companies/institutions are involved in vasculitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vasculitis?
Global Psoriatic Arthritis Treatment Market
Global Plaque Psoriasis Treatment Market
Global Psoriasis Treatment Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Vasculitis Pipeline
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Vasculitis Pipeline
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Vasculitis Pipeline: Epidemiology Snapshot
- 5.1 Vasculitis Pipeline Incidence by Key Markets
- 5.2 Vasculitis Pipeline – Patients Seeking Treatment in Key Markets
- 6 Vasculitis Pipeline: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Vasculitis Pipeline: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Vasculitis Pipeline, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Vasculitis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Vasculitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Benralizumab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Upadacitinib
- 10.2.3 Other Drugs
- 11 Vasculitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Sparsentan
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Vasculitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: BDB-001 injection, Drug: Cyclophosphamide, Drug: Glucocorticoids
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: MT-2990
- 12.2.3 Other Drugs
- 13 Vasculitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Vasculitis, Key Drug Pipeline Companies
- 14.1 AstraZeneca plc
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Smith & Nephew, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Abbvie Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Novartis Pharmaceuticals
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
